Nektar Therapeutics (NKTR)
1.315
-0.06
(-4.01%)
USD |
NASDAQ |
Nov 12, 15:25
Nektar Therapeutics Revenue (TTM): 93.16M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 93.16M |
| March 31, 2024 | 90.17M |
| December 31, 2023 | 90.12M |
| September 30, 2023 | 88.26M |
| June 30, 2023 | 87.74M |
| March 31, 2023 | 88.83M |
| December 31, 2022 | 92.06M |
| September 30, 2022 | 95.04M |
| June 30, 2022 | 96.34M |
| March 31, 2022 | 103.08M |
| December 31, 2021 | 101.91M |
| September 30, 2021 | 100.36M |
| June 30, 2021 | 105.47M |
| March 31, 2021 | 125.99M |
| December 31, 2020 | 152.92M |
| September 30, 2020 | 163.32M |
| June 30, 2020 | 162.50M |
| March 31, 2020 | 136.97M |
| December 31, 2019 | 114.62M |
| September 30, 2019 | 120.58M |
| June 30, 2019 | 119.12M |
| March 31, 2019 | 1.184B |
| December 31, 2018 | 1.193B |
| September 30, 2018 | 1.249B |
| June 30, 2018 | 1.374B |
| Date | Value |
|---|---|
| March 31, 2018 | 321.00M |
| December 31, 2017 | 307.71M |
| September 30, 2017 | 249.70M |
| June 30, 2017 | 133.10M |
| March 31, 2017 | 131.28M |
| December 31, 2016 | 165.44M |
| September 30, 2016 | 167.36M |
| June 30, 2016 | 190.97M |
| March 31, 2016 | 180.86M |
| December 31, 2015 | 230.78M |
| September 30, 2015 | 210.97M |
| June 30, 2015 | 283.88M |
| March 31, 2015 | 289.74M |
| December 31, 2014 | 200.71M |
| September 30, 2014 | 212.30M |
| June 30, 2014 | 140.34M |
| March 31, 2014 | 145.69M |
| December 31, 2013 | 148.92M |
| September 30, 2013 | 138.92M |
| June 30, 2013 | 96.42M |
| March 31, 2013 | 86.25M |
| December 31, 2012 | 81.19M |
| September 30, 2012 | 75.83M |
| June 30, 2012 | 84.48M |
| March 31, 2012 | 78.13M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
87.74M
Minimum
Jun 2023
163.32M
Maximum
Sep 2020
109.94M
Average
100.36M
Median
Sep 2021
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Esperion Therapeutics Inc | 277.79M |
| NovaBay Pharmaceuticals Inc | 12.02M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |